Adjuvant Study of high-risk Muscle Invasive Urothelial Carcinoma Open-label, multicenter, randomized Phase III Study with Atezolizumab (Anti-PD-L1 Antibody) as adjuvant Therapy compared with Observation in Patients with high-risk Muscle Invasive Urothelial Carcinoma after Surgical Resection (IMvigor010) Study AB 53/15 of the AUO

被引：0
作者：
Rexer, H. [1 ]
Retz, M. [2 ]
Albers, P. [3 ]
机构：
[1] MeckEvidence, AUO Geschaftsstelle, Seestr 11, D-17252 Schwarz, Germany
[2] Tech Univ Munich, Klinikum Rechts Isar, Urol Klin & Poliklin, Munich, Germany
[3] Univ Klinikum Dusseldorf, Urol Klin, Dusseldorf, Germany
来源：
UROLOGE | 2016年 / 55卷 / 11期
关键词：
D O I：
10.1007/s00120-016-0248-5
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1491 / 1493
页数：3
相关论文
共 50 条
  • [31] INTerpath-005: Phase II study of pembrolizumab (pembro) with V940 (mRNA-4157) versus pembro with placebo (pbo) for adjuvant treatment of resected high-risk muscle-invasive urothelial carcinoma (MIUC)
    Sonpavde, G. P.
    Perez Valderrama, B.
    Chamie, K.
    Gupta, S.
    De Santis, M.
    Meehan, R.
    Posadas, T.
    Ren, Y.
    Bavle, A.
    Powles, T. B.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S1164 - S1164
  • [32] A phase III study of INCB054828 as adjuvant therapy in patients (pts) with high-risk urothelial carcinoma (UC) harboring fibroblast growth factor receptor 3 (FGFR3) genomic alterations
    Necchi, A.
    Perez-Gracia, J. L.
    Loriot, Y.
    Witjes, W.
    Montorsi, F.
    Bjartell, A.
    Shariat, S. F.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [33] Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score
    Galsky, Matthew D.
    Bajorin, Dean F.
    Witjes, Johannes Alfred
    Gschwend, Juergen E.
    Tomita, Yoshihiko
    Nasroulah, Federico
    Li, Jun
    Collette, Sandra
    Valderrama, Begona P.
    Grimm, Marc-Oliver
    Appleman, Leonard
    Gravis, Gwenaelle
    Necchi, Andrea
    Ye, Dingwei
    Stenner, Frank
    Wind-Rotolo, Megan
    Zhang, Joshua
    Unsal-Kacmaz, Keziban
    [J]. EUROPEAN UROLOGY, 2023, 83 (05) : 432 - 440
  • [34] A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial DUrvalumab injection-1 study): clinical trial protocol
    Moe, Andrew
    Liow, Elizabeth
    Redfern, Andrew
    Swarbrick, Nicole
    Ferguson, Tom
    Davis, Ian D.
    Hayne, Dickon
    [J]. BJU INTERNATIONAL, 2021, 128 : 9 - 17
  • [35] Health-related quality of life (HRQoL) with adjuvant nivolumab (NIVO) vs placebo (PBO) after radical resection for high-risk muscle-invasive urothelial carcinoma (MIUC): results from the phase 3 CheckMate 274 trialep138
    Gschwend, J. E.
    Bajorin, D.
    Galsky, M.
    Broughton, E.
    Braverman, J.
    Koon, H.
    Maira-Arce, M.
    Hamilton, M.
    Shi, L.
    Guo, S.
    Witjes, J. A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 263 - 264
  • [36] SUNRISE-5: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF TAR-200 COMPARED WITH INTRAVESICAL CHEMOTHERAPY AFTER BACILLUS CALMETTE-GUERIN IN RECURRENT HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER
    Sima, Porten
    Sumeet, Bhanvadia
    Saltanat, Najmi
    Hussein, Sweiti
    John, Maffeo
    Kate, Stromberg
    Jovita, Gale
    Benjamin, Pradere
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [37] PURE01: An open label, single-arm, phase 2 study of the anti-programmed death (PD)-1 monoclonal antibody (moAb) pembrolizumab for neoadjuvant therapy of muscle-invasive urothelial bladder carcinoma (miUBC)
    Necchi, A.
    Mariani, L.
    Anichini, A.
    Giannatempo, P.
    Raggi, D.
    Togliardi, E.
    Calareso, G.
    Di Genova, N.
    Crippa, F.
    Salvioni, R.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [38] UPDATE OF TRUCE-02: AN OPEN LABEL, SINGLE-ARM, PHASE 2 STUDY OF TILELIZUMAB COMBINED WITH NAB-PACLITAXEL FOR HIGH-RISK NON-MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA (HR-NMIBC) WHICH IS NOT COMPLETELY RESECTABLE
    Hu, Hailong
    Niu, Yuanjie
    Wang, Haitao
    Shen, Chong
    Da, La
    Zhao, Gangjian
    Wang, Lili
    Wu, Zhouliang
    Zhang, Zhe
    Li, Zhi
    Jiang, Zhan
    Zhan, Xuejian
    Yang, Shaobo
    [J]. JOURNAL OF UROLOGY, 2022, 207 (05) : E1010 - E1010
  • [39] Phase 1/2 INTerpath-005 study: V940 (mRNA-4157) plus pembrolizumab with or without enfortumab vedotin (EV) for resected high-risk muscle-invasive urothelial carcinoma (MIUC).
    Sonpavde, Guru P.
    Valderrama, Begona P.
    Chamie, Karim
    Gupta, Shilpa
    De Santis, Maria
    Banerjee, Joydeep K.
    Ojalvo, Laureen
    Ren, Yixin
    Bavle, Abhishek
    Powles, Thomas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS893 - TPS893
  • [40] Tislelizumab combined with gemcitabine and cisplatin (GC) as adjuvant therapy in patients with high-risk upper urothelial carcinoma (UTUC) after surgery: A 2-year follow-up, real-world study
    Quan, Penghe
    Hou, Haozhong
    Yang, Xiaojian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345